Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aminopromazine is a small molecule drug of the phenothiazine class, structurally related to other phenothiazines such as promazine and chlorpromazine. It has been used primarily in veterinary medicine, particularly for cats and dogs, to reduce excessive smooth muscle contractions and manage urethral spasms associated with urolithiasis. Its mechanism of action is presumed similar to other phenothiazines, likely involving antagonism at dopamine receptors and possibly serotonin receptors, leading to sedative and antispasmodic effects. Aminopromazine has reached up to Phase II clinical trials but does not appear widely approved for human use[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aminopromazine.